BRAIN Biotech Stock

BRAIN Biotech FCF Margin

The Free Cash Flow Margin of BRAIN Biotech (BNN.DE) as of Aug 23, 2026 is -21.69 %. In the previous year, Free Cash Flow Margin was -9.72 % — a change of 123.09% (lower).

FCF Margin

-21.69 %

YoY

123.09%

Last updated:

Free Cash Flow Margin of BRAIN Biotech is 2026 -21.69 % . Free Cash Flow Margin of BRAIN Biotech was 2025 -9.72 % . It decreases by 123.09% lower compared to the previous year.

The BRAIN Biotech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-25.62 EUR
Jan 1, 2019
-25.98 EUR
Jan 1, 2020
-19.95 EUR
Jan 1, 2021
-13.46 EUR
Jan 1, 2022
-15.28 EUR
Jan 1, 2023
-12.39 EUR
Jan 1, 2024
-9.72 EUR
Jan 1, 2025
-21.69 EUR
The BRAIN Biotech FCF Margin history
YEARFCF MarginYoY
-21.69 %+123.09%
-9.72 %-21.52%
-12.39 %-18.94%
-15.28 %+13.53%
-13.46 %-32.52%
-19.95 %-23.20%
-25.98 %+1.39%
-25.62 %-9.64%
-28.36 %-34.82%
-43.50 %+95.39%
-22.26 %-34.25%
-33.86 %
Access this data via the Eulerpool API

BRAIN Biotech Stock analysis

What does BRAIN Biotech do? The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BRAIN Biotech stock

Free Cash Flow Margin of BRAIN Biotech is -21.69 % in 2026.

Free Cash Flow Margin of BRAIN Biotech changed from -9.72 % to -21.69 %, representing a 123.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin BRAIN Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's BRAIN Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — BRAIN Biotech

All Key Metrics — BRAIN Biotech